Opinion|Videos|February 20, 2024
Future Directions and Unmet Needs in Relapsed/Refractory MCL
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
3
Revisit Every OncLive On Air Episode From September 2026
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5